Wendy L. Dixon - 17 Jun 2022 Form 4/A - Amendment Insider Report for Black Diamond Therapeutics, Inc. (BDTX)

Role: Director
Signature: /s/ Brent Hatzis-Schoch, Attorney-in-Fact
Issuer symbol: BDTX
Transactions as of: 17 Jun 2022
Net transactions value: +$10,040
Form type: 4/A - Amendment
Filing time: 30 Jun 2022, 16:07:12 UTC
Date Of Original Report: 17 Jun 2022
Previous filing: 21 Jun 2022
Next filing: 19 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BDTX	Common Stock	Award	$10,040	+4,946		$2.03	4,946	17 Jun 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares were issued in accordance with the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.
F2	The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 16, 2022.

Remarks:

On June 17, 2022 the Reporting Person filed a Form 4 (the "Original Form 4"), which inadvertently understated the number of shares of Common Stock issued to the Reporting Person by 886 shares. This amendment is being filed to correct the amounts listed in Columns 4 and 5 of Table I, and there have been no other changes to the information presented in the Original Form 4.